"Contrary to initial research, new studies indicate that the benefits of the drug, which costs $8,000 a month, do not outweigh its risks, the advisory panel concluded."
On Mon, Aug 16, 2010 at 11:24 AM, Sam <sammyc...@gmail.com> wrote: > > What death panels? > > > http://www.washingtonpost.com/wp-dyn/content/article/2010/08/15/AR2010081503466.html?hpid=topnews > > Federal regulators are considering taking the highly unusual step of > rescinding approval of a drug that patients with advanced breast > cancer turn to as a last-ditch hope. > > The debate over Avastin, prescribed to about 17,500 women with breast > cancer a year, has become entangled in the politically explosive > struggle over medical spending and effectiveness that flared during > the battle over health-care reform: How should the government balance > protecting patients and controlling costs without restricting access > to cutting-edge, and often costly, treatments? > > ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~| Order the Adobe Coldfusion Anthology now! http://www.amazon.com/Adobe-Coldfusion-Anthology-Michael-Dinowitz/dp/1430272155/?tag=houseoffusion Archive: http://www.houseoffusion.com/groups/cf-community/message.cfm/messageid:325087 Subscription: http://www.houseoffusion.com/groups/cf-community/subscribe.cfm Unsubscribe: http://www.houseoffusion.com/groups/cf-community/unsubscribe.cfm
